DEA Scrambles to Defend Marijuana Decision Amid Supreme Court Ruling, Legal Collapse And Public Outrage
"They're defending a hearing that never actually happened," said Duane Boise."We followed every rule. They followed none."
WASHINGTON, D.C. / / July 27, 2025 / Friday, the U.S. Drug Enforcement Administration (DEA) filed a last-minute response in an escalating legal battle with MMJ BioPharma Cultivation, a Rhode Island-based pharmaceutical company seeking to grow federally compliant cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis.
The agency's filing comes in response to MMJ's official legal "exceptions" challenging a controversial ruling by DEA Chief Administrative Law Judge John Mulrooney II (aka Mclooney) - a ruling that denied MMJ's bulk manufacturing registration without a hearing, without cross-examination, and without admitting material evidence into the record.
"We were stonewalled at every step," said Duane Boise, CEO of MMJ BioPharma. "The DEA ignored Supreme Court precedent, blocked our science, and manipulated the process to produce a predetermined outcome. Now they're trying to defend that decision in a system the Department of Justice itself has declared unconstitutional."
Constitutional Crisis
MMJ's case has become a flashpoint in the broader collapse of the DEA's internal court system. In Axon v. FTC (2023) and Jarkesy v. SEC (2024), the U.S. Supreme Court ruled that agency administrative law judges (ALJs) violate the separation of powers because they are insulated from presidential removal - a direct hit to the DEA's current process.
Even the Department of Justice has abandoned its defense of the ALJ structure, and Attorney General Pam Bondi notified the courts in February 2025 that DEA hearings like the one against MMJ BioPharma Cultivation are legally void.
DEA's Desperate Defense
Despite this, the DEA has now used its one allotted legal filing to respond to MMJ's exceptions - an effort seen by legal experts as a last-ditch attempt to salvage a crumbling decision and maintain bureaucratic control over cannabis based drug development.
"This is the DEA doubling down on injustice," said Boise. "They're defending a hearing that never actually happened because they're afraid of what the truth will show."
A Legitimate Researcher, Blocked
MMJ BioPharma Cultivation is not a dispensary. It is a federally compliant manufacturer that has:
FDA Orphan Drug Designation
Two accepted Investigational New Drug (IND) applications
A pharmaceutical grade cannabis facility built to DEA standards
Binding supply agreements with Schedule I licensees
Yet after more than 2,400 days of delays, the DEA still refuses to approve its registration - while unlicensed tribal and cartel-linked marijuana networks operate with impunity across state lines, and recreational cannabis companies receive preferential treatment.
Path Forward: Will Administrator Terrance Cole Act?
All eyes now turn to Terrance Cole, President Trump's newly confirmed DEA Administrator, who holds the final authority to approve or deny MMJ's license.
"Administrator Cole has a choice," said Boise. "He can defend a broken system riddled with bias and constitutional violations-or he can restore integrity by granting our lawful, science backed registration and ending seven years of obstruction."
MMJ BioPharma has vowed to take its case as far as necessary, including seeking federal injunctions and legislative reform if the DEA continues to block research.
About MMJ BioPharma Cultivation
MMJ BioPharma is a federally compliant biopharmaceutical company focused on producing cannabis derived medicines for neurodegenerative diseases. It operates under FDA regulatory frameworks and maintains partnerships with international GMP manufacturers and licensed U.S. laboratories.
MMJ is represented by attorney Megan Sheehan.
CONTACT:Madison HiseyMHisey@mmjih.com203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Chevron's (CVX) Strong Asset Outlook Offsets Lower Oil Prices, Says UBS
Chevron Corporation (NYSE:CVX) ranks among the . UBS reaffirmed its Buy rating and price target of $177 on Chevron Corporation (NYSE:CVX) on July 11 in anticipation of the oil giant's 2025 second-quarter earnings report. Given the decline in oil prices, the investment bank expects Chevron to post reduced quarter-over-quarter profitability. However, it also expects its Permian Basin, Gulf of America, and Tengizchevroil (TCO) assets to perform well. Pixabay/Public Domain The planned acquisition of Hess Corporation was the main focus of Chevron Corporation (NYSE:CVX) investors, according to UBS, which predicted the transaction would conclude in the third quarter of 2025. The next major event after the Hess merger is Chevron's November Analyst Day, where, according to the investment bank, the company is likely to present its growth strategy. Chevron Corporation (NYSE:CVX), based in San Ramon, California, is a major American global energy company that specializes in the oil and gas industry. Founded as the Standard Oil Company of California, it is the second-largest direct descendant of Standard Oil. While we acknowledge the potential of CVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Several US executives to visit China this week: sources
By Laurie Chen BEIJING (Reuters) -A high-level delegation of American executives will travel to China this week to meet senior Chinese officials in a trip organised by the U.S.-China Business Council (USCBC), two sources with knowledge of the visit told Reuters on Monday. The visit coincides with the latest round of U.S.‑China trade negotiations in Sweden, where China's Vice Premier He Lifeng is meeting U.S. officials from July 27 to July 30 for a new round of economic and trade talks. The delegation will be led by FedEx Chief Executive Rajesh Subramaniam, the council's board chair, one of the sources briefed on the trip said. The South China Morning Post first reported the visit on Sunday, saying that executives from firms including Boeing would be part of the delegation. Reuters could not confirm other CEO members of the delegation or which Chinese officials they would meet. Boeing declined to comment on the trip and deferred to USCBC. The U.S. government was not involved in the organisation of the visit, one of the sources said. The trip comes as Beijing and Washington work towards a summit between the two countries' leaders later this year, probably around the time of the APEC forum in South Korea October 26 - November 1, sources previously told Reuters. USCBC did not respond immediately to a request for comment. The business lobby previously organised similar visits to China by American CEO delegations in 2023 and 2024. The 2024 trip, also led by Subramaniam, included meetings with He and Foreign Minister Wang Yi, where executives discussed issues including market access. China faces an August 12 deadline to reach a durable deal with the White House or risk higher U.S. tariffs. U.S. officials are likely to extend the deadline by another 90 days as both sides work towards a more comprehensive deal, sources previously told Reuters. An extension of that length would prevent further escalation and help create conditions for the potential meeting between Trump and Chinese President Xi Jinping. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
18 minutes ago
- Yahoo
Trump pauses export controls to bolster China trade deal, FT says
(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
